AI blood test could spot deadly clotting complication in sepsis patients
NCT ID NCT07630415
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to validate a new blood test that uses artificial intelligence to detect disseminated intravascular coagulation (DIC) early in patients with septic shock. DIC is a severe clotting disorder that often leads to death, but current diagnostic methods are complex and rarely used. The test measures a specific blood cell signal and combines it with AI to provide a faster, more reliable diagnosis. Researchers will enroll 492 adults in intensive care to see if this approach works better than existing tools.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neutrophil fluorescence test and AI model
What this could lead to
If successful, this could give doctors a simple, fast blood test to catch a deadly complication of sepsis early, potentially saving lives.
What could go wrong
This is an early validation study, not a treatment trial. The test may not prove accurate enough in real-world intensive care settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University Hospitals of Strasbourg, Intensive Care Medicine Department - New Civil Hospital
Strasbourg, 67098, France